424 related articles for article (PubMed ID: 30287808)
1. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers.
Zhang Y; Zheng D; Zhou T; Song H; Hulsurkar M; Su N; Liu Y; Wang Z; Shao L; Ittmann M; Gleave M; Han H; Xu F; Liao W; Wang H; Li W
Nat Commun; 2018 Oct; 9(1):4080. PubMed ID: 30287808
[TBL] [Abstract][Full Text] [Related]
2. A novel GRK3-HDAC2 regulatory pathway is a key direct link between neuroendocrine differentiation and angiogenesis in prostate cancer progression.
Naderinezhad S; Zhang G; Wang Z; Zheng D; Hulsurkar M; Bakhoum M; Su N; Yang H; Shen T; Li W
Cancer Lett; 2023 Sep; 571():216333. PubMed ID: 37543278
[TBL] [Abstract][Full Text] [Related]
3. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.
Sang M; Hulsurkar M; Zhang X; Song H; Zheng D; Zhang Y; Li M; Xu J; Zhang S; Ittmann M; Li W
Oncotarget; 2016 Jul; 7(29):45171-45185. PubMed ID: 27191986
[TBL] [Abstract][Full Text] [Related]
4. LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.
Luo J; Wang K; Yeh S; Sun Y; Liang L; Xiao Y; Xu W; Niu Y; Cheng L; Maity SN; Jiang R; Chang C
Nat Commun; 2019 Jun; 10(1):2571. PubMed ID: 31189930
[TBL] [Abstract][Full Text] [Related]
5. Loss of EHF facilitates the development of treatment-induced neuroendocrine prostate cancer.
Long Z; Deng L; Li C; He Q; He Y; Hu X; Cai Y; Gan Y
Cell Death Dis; 2021 Jan; 12(1):46. PubMed ID: 33414441
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST.
Li W; Zheng D; Zhang Y; Yang S; Su N; Bakhoum M; Zhang G; Naderinezhad S; Mao Z; Wang Z; Zhou T
Res Sq; 2023 Oct; ():. PubMed ID: 37886478
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
[TBL] [Abstract][Full Text] [Related]
8. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
9. DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2.
Kaarijärvi R; Kaljunen H; Nappi L; Fazli L; Kung SHY; Hartikainen JM; Paakinaho V; Capra J; Rilla K; Malinen M; Mäkinen PI; Ylä-Herttuala S; Zoubeidi A; Wang Y; Gleave ME; Hiltunen M; Ketola K
Commun Biol; 2024 Jan; 7(1):108. PubMed ID: 38238517
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST.
Zheng D; Zhang Y; Yang S; Su N; Bakhoum M; Zhang G; Naderinezhad S; Mao Z; Wang Z; Zhou T; Li W
Cell Death Discov; 2024 May; 10(1):246. PubMed ID: 38777812
[TBL] [Abstract][Full Text] [Related]
12. Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1.
Hulsurkar M; Li Z; Zhang Y; Li X; Zheng D; Li W
Oncogene; 2017 Mar; 36(11):1525-1536. PubMed ID: 27641328
[TBL] [Abstract][Full Text] [Related]
13. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
14. Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression.
Wang Z; Zhao Y; An Z; Li W
Front Oncol; 2019; 9():1491. PubMed ID: 32039001
[TBL] [Abstract][Full Text] [Related]
15. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
[TBL] [Abstract][Full Text] [Related]
16. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance.
Chen WY; Wen YC; Lin SR; Yeh HL; Jiang KC; Chen WH; Lin YS; Zhang Q; Liew PL; Hsiao M; Huang J; Liu YN
Commun Biol; 2021 Jan; 4(1):22. PubMed ID: 33398073
[TBL] [Abstract][Full Text] [Related]
17. Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
[TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.
Lipianskaya J; Cohen A; Chen CJ; Hsia E; Squires J; Li Z; Zhang Y; Li W; Chen X; Xu H; Huang J
Asian J Androl; 2014; 16(4):541-4. PubMed ID: 24589459
[TBL] [Abstract][Full Text] [Related]
19. The β
Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
[TBL] [Abstract][Full Text] [Related]
20. Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer.
Shan J; Al-Muftah MA; Al-Kowari MK; Abuaqel SWJ; Al-Rumaihi K; Al-Bozom I; Li P; Chouchane L
Cell Death Discov; 2019; 5():139. PubMed ID: 31583122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]